Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL: iGlarLixi De-intensification in T2D
NCT04945070Phase 4Unknown
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Hemoglobin A1c at 6 months. Status: unknown.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04945070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945070.